Can emergency Ebola treatment centers close Africa’s outbreak response gap?
Find out how Samaritan’s Purse’s Ebola treatment deployment in Congo highlights urgent gaps in outbreak readiness and field care.
A rare disease policy shift just landed at the WHO. Could it change hemophilia care worldwide?
Find out how the WHO hemophilia resolution could reshape diagnosis, treatment access, prophylaxis and bleeding disorder care worldwide.
Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation
Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.
Is endometriosis diagnosis finally moving beyond surgery after years of missed symptoms?
Endometriosis testing is escaping the surgery-first era. Saliva, blood and imaging tools now face the harder test: clinical utility.
How Novartis Pharma AG is targeting the last untreated segment in malaria care
Discover how Novartis Pharma AG is targeting neonatal malaria with Coartem Baby and what WHO prequalification means for global access.
Why GC Biopharma’s BARYCELA approval in Guatemala matters beyond one Latin American market
GC Biopharma won Guatemala approval for BARYCELA. Read what this means for Latin America, vaccine supply strategy, and varicella market competition.